So, what is the rate limiting step in myelinisation? The B12/folate dependent enzymes?
From
http://www.lef.org/p...lerosis_02.htm:Vitamin B12. Vitamin B12 plays a key role in the generation of myelin. Studies have shown that patients with MS often have abnormally low levels of vitamin B12 in their cerebrospinal fluid and/or blood serum (Reynolds EH 1992). In fact, clinical vitamin B12 deficiency and MS share remarkably similar characteristics, occasionally rendering correct diagnosis difficult (Miller A et al 2005). For more than three decades, many physicians have prescribed vitamin B12 injections for patients who have MS. Patients who have received vitamin B12 supplements have reportedly experienced consistent clinical improvements in their symptoms (Kidd PM 2001).
In the United Kingdom , researchers investigated the effects of 6 months of vitamin B12 injections (1 mg/week) on 138 patients with MS, in a double-blind, placebo-controlled, randomized study. Patients were assessed using a standardized evaluation of neurological disability. Although the treatment regimen also included the eventual addition of two other compounds, the researchers concluded that the conditions of patients with MS improved after starting vitamin B12 injections (Wade DT et al 2002).
They recommend up to 40mg B12 for Multiple Sclerosis treatment, but that would probably not benefit anyone with already healthy myelinisation?
...
Perhaps cAMP elevation may be a better target? Which could mean anything cAMP elevating like Forskolin, modified to pass the blood brain barrier, could be a potential myelination-enhancing nootropic.
http://linkinghub.el...896627302008267Elevation of cAMP can overcome myelin inhibitors to encourage regeneration of the CNS. We show that a consequence of elevated cAMP is the synthesis of polyamines, resulting from an up-regulation of Arginase I, a key enzyme in their synthesis. Inhibiting polyamine synthesis blocks the cAMP effect on regeneration. Either over-expression of Arginase I or exogenous polyamines can overcome inhibition by MAG and by myelin in general. While MAG/myelin support the growth of young DRG neurons, they become inhibitory as DRGs mature. Endogenous Arginase I levels are high in young DRGs but drop spontaneously at an age that coincides with the switch from promotion to inhibition by MAG/myelin. Over-expressing Arginase I in maturing DRGs blocks that switch. Arginase I and polyamines are more specific targets than cAMP for intervention to encourage regeneration after CNS injury.
Edited by mixter, 18 March 2009 - 02:31 PM.